Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers
Table 2
Cell surface marker phenotyping of immune cells between CS and controls.
Parameters
Controls (n = 16)
Cushing syndrome
(n = 26)
value
Monocytes
CD14++CD16− classical (MN)
42.2 ± 32.5
34.2 ± 30.1
0.082
CD14++CD16−11b+ (%)
80.8 ± 19.6
72.4 ± 32.4
0.227
CD14++CD16+ intermediate (MN)
28.7 ± 26.1
36.3 ± 25.1
0.047
CD14++CD16+11b+ (%)
48.1 ± 48.7
52.4 ± 44.8
0.432
CD14+CD16++ nonclassical (MN)
5.8 ± 3.8
7.1 ± 2.3
0.053
CD14+CD16++11b+ (%)
35.4 ± 41.1
38.4 ± 42.8
0.864
Neutrophils
CD15+ (% N)
47.1 ± 13.9
65.8 ± 24.6
0.027
CD15+CD16+ (%)
44.3 ± 12.7
66.6 ± 25.2
0.008
CD15+CD16+11b (%)
69.2 ± 29.1
80.6 ± 26.6
0.098
CD16+11b (% N)
94.2 ± 4.2
90.0 ± 22.7
0.460
Lymphocytes
CD3+CD8+ (% L)
26.8 ± 8.0
30.1 ± 11.9
0.435
CD3+CD4+ (% L)
54.2 ± 6.6
47.6 ± 18.6
0.207
CD3+CD4+CD25+ (%)
22.7 ± 11.1
20.7 ± 18.8
0.746
NK (% L)
18.4 ± 18.5
34.7 ± 32.2
0.019
NKCD11b+ (%)
37.5 ± 44.4
35.1 ± 36.0
0.889
Data are expressed as % ± standard deviation. MN: monocytes; N: neutrophils; L: lymphocytes. .
